CLAIMS

1. A method for treating cancer in an individual, the method comprising administering to the individual an effective amount of ADCX25 or ADCT-301 and Gemcitabine.

2. A first composition comprising ADCX25 or ADCT-301 for use in a method of treating cancer in an individual, wherein the treatment comprises administration of the first composition in combination with a second composition comprising Gemcitabine.

3. A first composition comprising Gemcitabine for use in a method of treating a disorder in an individual, wherein the treatment comprises administration of the first composition in combination with a second composition comprising ADCX25 or ADCT-301.

4. Use of ADCX25 or ADCT-301 in the manufacture of a medicament for treating cancer in an individual, wherein the medicament comprises ADCX25 or ADCT-301, and wherein the treatment comprises administration of the medicament in combination with a composition comprising Gemcitabine.

5. Use of Gemcitabine antagonist in the manufacture of a medicament for treating cancer in an individual, wherein the medicament comprises Gemcitabine, and wherein the treatment comprises administration of the medicament in combination with a composition comprising ADCX25 or ADCT-301.

6. A kit comprising:
a first medicament comprising ADCX25 or ADCT-301;
a second medicament comprising Gemcitabine; and, optionally,
a package insert comprising instructions for administration of the first medicament to an individual in combination with the second medicament for the treatment of cancer.

7. A kit comprising a medicament comprising ADCX25 or ADCT-301 and a package insert comprising instructions for administration of the medicament to an individual in combination with a composition comprising Gemcitabine for the treatment of cancer.

8. A kit comprising a medicament comprising Gemcitabine and a package insert comprising instructions for administration of the medicament to an individual in combination with a composition comprising ADCX25 or ADCT-301 for the treatment of cancer.

9. A pharmaceutical composition comprising ADCX25 or ADCT-301 and Gemcitabine.

10. A method of treating cancer in an individual, the method comprising administering to the individual an effective amount of the composition of claim 9.

11. The composition of claim 9 for use in a method of treating cancer in an individual.

12. The use of the composition of claim 9 in the manufacture of a medicament for treating cancer in an individual.

13. A kit comprising the composition of claim 9 and a set of instructions for administration of the medicament to an individual for the treatment of cancer.

14. The composition, method, use, or kit according to any previous claim, wherein the treatment comprises administering ADCX25 or ADCT-301 before Gemcitabine, simultaneous with Gemcitabine, or after Gemcitabine.

15. The composition, method, use, or kit according to any previous claim, wherein the treatment further comprises administering a chemotherapeutic agent.

16. The composition, method, use, or kit according to any previous claim, wherein the individual is human.

17. The composition, method, use, or kit according to any previous claim, wherein the individual has, or has been determined to have, cancer.

18. The composition, method, use, or kit according any previous claim, wherein the individual has, or has been has been determined to have, a cancer characterised by the presence of a neoplasm comprising both CD25+ve and CD25-ve cells.

19. The composition, method, use, or kit according any previous claim, wherein the individual has, or has been has been determined to have, a cancer characterised by the presence of a neoplasm comprising, or composed of, CD25-ve neoplastic cells.

20. The composition, method, use, or kit according to any previous claim, wherein the cancer or neoplasm is all or part of a solid tumour.

21. The composition, method, use, or kit according to any previous claim, wherein the individual has, or has been has been determined to have, a cancer which expresses CD25 or CD25+ tumour-associated non-tumour cells, such as CD25+ infiltrating T-cells.

22. The composition, method, use, or kit according to any previous claim, wherein the individual has, or has been has been determined to have, a cancer which expresses a low level of surface expression of CD25.

23. The composition, method, use, or kit according to any preceding claim, wherein the individual has, or has been has been determined to have, a cancer which expresses a second target protein.

24. The composition, method, use, or kit according to any one of the preceding claims, wherein the treatment:

a) effectively treats a broader range of disorders,
b) effectively treats resistant, refractory, or relapsed disorders,
c) has an increased response rate, and / or
d) has increased durability;

as compared to treatment with either ADCX25 or ADCT-301 or Gemcitabine alone.

25. The composition, method, use, or kit according to any one of the preceding claims, wherein the cancer is selected from the group comprising:

Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);

leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);

pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.